Next Article in Journal
Treatment of Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis with Lenalidomide in a Patient testing Negative for 5q Deletion and JAK2 V617F and MPL W515K/L Mutations
Previous Article in Journal
Positive Impact of Eculizumab Therapy on Surgery for Budd- Chiari Syndrome in a Patient with Paroxysmal Nocturnal Hemoglobinuria and a Longterm History of Thrombosis
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides

1
University of Pittsburgh Medical Center Altoona, Pittsburgh, PA 15213, USA
2
Department of Dermatology, University of Pittsburgh, 5th Floor, Suite 500.68, 3708 Fifth Avenue, Pittsburgh, PA 15213, USA
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2016, 8(4), 54-55; https://doi.org/10.4081/hr.2016.6840
Submission received: 16 August 2016 / Revised: 20 September 2016 / Accepted: 11 October 2016 / Published: 2 November 2016

Abstract

Romidepsin belongs to a class of medications called histone deacetylase inhibitors and is currently approved for treatment of cutaneous and peripheral T-cell lymphomas. Romidepsin was previously investigated for the treatment of chronic lymphocytic leukemia (CLL), and demonstrated potential benefit, but interest in its use declined following phase I clinical trials that showed poor tolerance of a significant side effect profile. We presented a patient with a history of stage II CLL, referred to dermatology for treatment of new-onset of mycosis fungoides (MF), who was treated with romidepsin over seven months. The patient achieved a partial response with 50% decrease in body surface area occupied by MF, thinning of remaining plaques, and near complete response in his CLL. His absolute lymphocyte count remained within the normal range for four months following discontinuation of romidepsin. Side effects were well-tolerated and did not limit therapy. Current literature on romidepsin is reviewed and compared to existing treatments for CLL.
Keywords: chronic lymphocytic leukemia; histone deacetylase inhibitors; Romidepsin chronic lymphocytic leukemia; histone deacetylase inhibitors; Romidepsin

Share and Cite

MDPI and ACS Style

Lemchak, D.M.; Akilov, O.E. Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides. Hematol. Rep. 2016, 8, 54-55. https://doi.org/10.4081/hr.2016.6840

AMA Style

Lemchak DM, Akilov OE. Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides. Hematology Reports. 2016; 8(4):54-55. https://doi.org/10.4081/hr.2016.6840

Chicago/Turabian Style

Lemchak, David M., and Oleg E. Akilov. 2016. "Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides" Hematology Reports 8, no. 4: 54-55. https://doi.org/10.4081/hr.2016.6840

APA Style

Lemchak, D. M., & Akilov, O. E. (2016). Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides. Hematology Reports, 8(4), 54-55. https://doi.org/10.4081/hr.2016.6840

Article Metrics

Back to TopTop